To lower the risk of ischemic events, such as stent thrombosis (ST) and recurrent myocardial infarction (MI), recent guidelines in Europe and the United States recommend DAPT with aspirin and a P2Y12 inhibitor (clopidogrel, prasugrel, and ticagrelor) for up to 12 months (6–8). This evidence concerns the gene P2RY12 and myocardial infarction.